A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Sorafenib (Primary)
- Indications Fibroma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jan 2019.
- 02 Dec 2016 Status changed from suspended to active, no longer recruiting.